Exhibit 99.1 TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Early data on patients treated in Cohort C of the ALLOHA™ Phase 1 heme trial expected in the second quarter of 2026 Initiation of Phase 3 study of TSC-101 (ALLOHA-2™) planned for the second quarter of 2026 Initiation of Phase 1 study of TSC-102-A01 and TSC-102-A03 targeting CD45 in patients with HLA types A01:01 and A03:01 planned for the second half of 2026 Chrystal U. Louis, M.D., Chief Medical Off ...